Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $5.9 million.

  • Heron Therapeutics' Other Non-Current Assets fell 1230.06% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 1230.06%. This contributed to the annual value of $6.5 million for FY2024, which is 2023.87% down from last year.
  • Heron Therapeutics' Other Non-Current Assets amounted to $5.9 million in Q3 2025, which was down 1230.06% from $6.1 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Other Non-Current Assets peaked at $18.0 million during Q1 2022, and registered a low of $346000.0 during Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Assets was $7.9 million (2024), whereas its average is $9.1 million.
  • As far as peak fluctuations go, Heron Therapeutics' Other Non-Current Assets soared by 509566.47% in 2022, and later tumbled by 5171.14% in 2023.
  • Quarter analysis of 5 years shows Heron Therapeutics' Other Non-Current Assets stood at $17.7 million in 2021, then dropped by 11.34% to $15.7 million in 2022, then crashed by 48.27% to $8.1 million in 2023, then decreased by 20.24% to $6.5 million in 2024, then fell by 9.27% to $5.9 million in 2025.
  • Its Other Non-Current Assets stands at $5.9 million for Q3 2025, versus $6.1 million for Q2 2025 and $6.3 million for Q1 2025.